MGTA-145

MGTA-145 is a truncated form of the chemokine growth-related oncogene beta (gro-beta truncate, GROβT) and acts as an agonist of the CXC chemokine receptor type 2 (CXCR2). It is being developed primarily for the rapid mobilization of hematopoietic stem cells (HSCs) from bone marrow into peripheral blood, facilitating their collection for autologous or allogeneic transplantation. Upon intravenous administration, MGTA-145 binds to and activates CXCR2 on neutrophils, leading to the release of matrix metalloproteinase-9 (MMP-9), which in turn promotes HSC egress from bone marrow. When used in combination with plerixafor—a CXCR4 inhibitor—MGTA-145 has demonstrated synergistic effects in rapidly mobilizing robust numbers of CD34+ HSCs with a single dose and same-day apheresis. This approach offers potential advantages over traditional granulocyte colony-stimulating factor (G-CSF)-based regimens by reducing adverse effects and time required for mobilization. Clinical development has focused on indications such as multiple myeloma, sickle cell disease, acute myeloid leukemia, lymphoblastic leukemia/lymphoma, myelodysplastic syndrome, kidney diseases, and healthy volunteers[4][5][6][8].

Other names

gro-beta truncateGROβT